What is a stock summary page? Click here for an overview.
Business Description
Kazia Therapeutics Ltd
ISIN : US48669G1058
Share Class Description:
KZIA: ADRDescription
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.61 | |||||
| Equity-to-Asset | -0.46 | |||||
| Debt-to-Equity | -0.06 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -12.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -61.1 | |||||
| 3-Year EBITDA Growth Rate | -26.6 | |||||
| 3-Year EPS without NRI Growth Rate | -20.3 | |||||
| 3-Year FCF Growth Rate | 25.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 43.72 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.05 | |||||
| 9-Day RSI | 43.83 | |||||
| 14-Day RSI | 41.6 | |||||
| 3-1 Month Momentum % | -36.22 | |||||
| 6-1 Month Momentum % | -83.67 | |||||
| 12-1 Month Momentum % | -75.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.24 | |||||
| Cash Ratio | 0.06 | |||||
| Days Sales Outstanding | 0.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.1 | |||||
| Shareholder Yield % | -81.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1243.44 | |||||
| Net Margin % | -1162.95 | |||||
| FCF Margin % | -417.16 | |||||
| ROE % | -1077.87 | |||||
| ROA % | -108.04 | |||||
| ROIC % | -123.85 | |||||
| 3-Year ROIIC % | 310.22 | |||||
| ROCE % | -290.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.31 | |||||
| EV-to-EBIT | -0.17 | |||||
| EV-to-EBITDA | -0.18 | |||||
| EV-to-Forward-EBITDA | -1.19 | |||||
| EV-to-Revenue | 2.11 | |||||
| EV-to-Forward-Revenue | 2.03 | |||||
| EV-to-FCF | -0.52 | |||||
| Earnings Yield (Greenblatt) % | -588.24 | |||||
| FCF Yield % | -164.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KZIA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kazia Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.533 | ||
| EPS (TTM) ($) | -33.83 | ||
| Beta | 1.63 | ||
| 3-Year Sharpe Ratio | -0.9 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | 114.01 | ||
| 14-Day RSI | 41.6 | ||
| 14-Day ATR ($) | 0.506084 | ||
| 20-Day SMA ($) | 3.59042 | ||
| 12-1 Month Momentum % | -75.21 | ||
| 52-Week Range ($) | 2.86 - 79 | ||
| Shares Outstanding (Mil) | 1.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kazia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kazia Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kazia Therapeutics Ltd Frequently Asked Questions
What is Kazia Therapeutics Ltd(KZIA)'s stock price today?
The current price of KZIA is $3.47. The 52 week high of KZIA is $79.00 and 52 week low is $2.86.
When is next earnings date of Kazia Therapeutics Ltd(KZIA)?
The next earnings date of Kazia Therapeutics Ltd(KZIA) is 2025-05-02 Est..
Does Kazia Therapeutics Ltd(KZIA) pay dividends? If so, how much?
Kazia Therapeutics Ltd(KZIA) does not pay dividend.
Guru Commentaries on NAS:KZIA
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers